Abiopharma

🔍 Bonfiglio Patrice Eadon (Executive)

Company: AMARIN CORP PLC\UK (AMRN)

Report Date: 2026-04-18

Detailed Transactions and Holdings:

• Acquired 838 shares of American Depositary Shares (Direct)
  Date: 2026-04-18 | Code: M | equity_swap_involved: false | shares_owned_after: 1,239.00 | transaction_form_type: 4 | Footnotes: F1, F2, F1, F3, F1
• Sold 403 shares of American Depositary Shares at $14.98 per share (Direct)
  Date: 2026-04-18 | Code: F | equity_swap_involved: false | shares_owned_after: 836.00 | transaction_form_type: 4 | Footnotes: F1, F4, F1, F1
• Acquired 838 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-18 | Code: M | equity_swap_involved: false | shares_owned_after: 838.00 | transaction_form_type: 4 | Footnotes: F5, F1, F2, F3, F1, F1, F1

Footnotes:

• F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.
• F2: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted 2,514 RSUs under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027.
• F3: Not applicable.
• F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
• F5: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.